The First Clinical Medical College of Zhejiang Chinese Medicine University, 310053, Hangzhou, China.
The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine (Zhejiang Province Hospital of Chinese Medicine), Hangzhou, 310006, China.
J Dermatol. 2023 May;50(5):575-587. doi: 10.1111/1346-8138.16791. Epub 2023 Mar 27.
Bullous pemphigoid (BP) is an autoimmune blistering disease associated with anti-BP180 and anti-BP230 antibodies. The pathogenic action mechanism of immunoglobulin E (IgE) antibodies in BP has been studied since the 1970s, and IgE antibodies have gradually been confirmed as being important in BP; therefore, anti-IgE therapy may be a new option for the treatment of BP. Omalizumab, as an IgE monoclonal antibody, has been increasingly used clinically to treat BP in recent years. Here, we collected 35 papers investigating omalizumab for BP treatment in a total of 83 patients, and the vast majority of patients showed varying degrees of improvement after treatment, except for a small number of patients with poor clinical outcomes. The patients were then divided into three groups according to dosing frequency and number of doses. Statistical analysis indicated that dosing frequency had little effect on clinical efficacy. While the groups with different numbers of doses were evaluated, the results concluded that clinical efficacy was affected by the number of doses, but there was no positive correlation between the number of doses and clinical efficacy.
大疱性类天疱疮（BP）是一种自身免疫性水疱病，与抗 BP180 和抗 BP230 抗体有关。自 20 世纪 70 年代以来，人们一直在研究免疫球蛋白 E（IgE）抗体在 BP 中的致病作用机制，IgE 抗体已逐渐被确认为 BP 的重要因素；因此，抗 IgE 治疗可能成为 BP 治疗的新选择。奥马珠单抗作为一种 IgE 单克隆抗体，近年来在临床上越来越多地用于治疗 BP。在这里，我们收集了 35 篇关于奥马珠单抗治疗 BP 的论文，共涉及 83 例患者，除少数患者临床结局不佳外，绝大多数患者治疗后均有不同程度的改善。然后根据给药频率和剂量数将患者分为三组。统计分析表明，给药频率对临床疗效影响不大。而在评估不同剂量组时，结果表明临床疗效受剂量数的影响，但剂量数与临床疗效之间没有正相关关系。
